The use of a tumor colony assay in predicting chemotherapeutic drug response in murine bladder cancer
- 15 August 1983
- Vol. 52 (4) , 619-625
- https://doi.org/10.1002/1097-0142(19830815)52:4<619::aid-cncr2820520408>3.0.co;2-9
Abstract
A tumor colony assay (TCA) was evaluated for its ability to predict anticancer drug responses in an N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT)-induced murine bladder tumor (MBT) model. Ten anticancer drugs were evaluated in vitro and in vitro using four MBT cell lines (40 drug responses). Using the optimum criteria for drug response, the TCA accurately predicted drug responses in the murine model 65% of the time with a true-positive predictive rate of 54% and a true-negative predictive rate of 70%. Drug testing tumor cells immediately on removal from the mouse resulted in a true-positive predictive rate of 77% and a true-negative predictive rate of 100%. The authors conclude that the TCA can predict response to chemotherapy in the MBT model and may be useful in screening investigation compounds for the subsequent evaluation in this murine bladder tumor model.This publication has 8 references indexed in Scilit:
- The Clonogenic Growth of Cells Derived From Bladder Barbotage in Patients With Transitional Cell Carcinoma of the Bladder: A Preliminary ReportJournal of Urology, 1982
- Growth characteristics of N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT)-induced mouse bladder tumor lines in a human tumor stem cell assayCancer, 1982
- Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapyThe American Journal of Medicine, 1981
- The Treatment of Advanced Bladder Cancer with MethotrexateBritish Journal of Urology, 1977
- Primary Bioassay of Human Myeloma Stem CellsJournal of Clinical Investigation, 1977
- CIS-DICHLORODIAMMINEPLATINUM(II) IN ADVANCED BLADDER CANCER1976
- The Use of Methotrexate in Advanced Carcinoma of the BladderJournal of Urology, 1972